Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accounts Payables (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Accounts Payables for 8 consecutive years, with $10.3 million as the latest value for Q1 2026.

  • Quarterly Accounts Payables rose 22.58% to $10.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Feb 2026, up 22.58% year-over-year, with the annual reading at $11.2 million for FY2025, 2.33% down from the prior year.
  • Accounts Payables for Q1 2026 was $10.3 million at Nurix Therapeutics, down from $11.2 million in the prior quarter.
  • The five-year high for Accounts Payables was $11.5 million in Q4 2024, with the low at $2.2 million in Q3 2023.
  • Average Accounts Payables over 5 years is $6.5 million, with a median of $6.0 million recorded in 2022.
  • The sharpest move saw Accounts Payables crashed 63.87% in 2023, then surged 119.73% in 2025.
  • Over 5 years, Accounts Payables stood at $5.1 million in 2022, then grew by 26.4% to $6.4 million in 2023, then skyrocketed by 79.38% to $11.5 million in 2024, then fell by 2.33% to $11.2 million in 2025, then dropped by 8.22% to $10.3 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $10.3 million, $11.2 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.